ProCE Banner Activity

KEYNOTE-826: Subgroup Analysis of Pembrolizumab + Chemotherapy ± Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer

Slideset Download
Conference Coverage
Pembrolizumab + chemotherapy ± bevacizumab prolonged PFS and OS vs placebo + chemotherapy ± bevacizumab in key patient populations, including those defined by bevacizumab use, histology, platinum use, and prior chemoradiotherapy.

Released: June 09, 2022

Expiration: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab